- Home
- ABTS vs BIVI Comparison
ABTS vs BIVI Comparison
Compare ABTS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | BIVI |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 14.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABTS | BIVI |
|---|---|---|
| Price | $6.02 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.5K | ★ 71.9K |
| Earning Date | 08-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,037,156.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.69 | N/A |
| 52 Week Low | $1.35 | $1.25 |
| 52 Week High | $14.10 | $30.90 |
Technical Indicators
Market Signals| Indicator | ABTS | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 49.94 |
| Support Level | $5.67 | $1.45 |
| Resistance Level | $6.74 | $1.70 |
| Average True Range (ATR) | 0.66 | 0.10 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 58.38 | 67.78 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.